<DOC>
	<DOCNO>NCT01624376</DOCNO>
	<brief_summary>The primary objective study investigate safety tolerability locally administer DLX105 treat enterocutaneous fistula Crohn 's Disease patient . The study consist screen period approx . 2 week , 4-week treatment period 2-week follow-up period . An end-of study visit schedule Day 43 , 2 week last study visit .</brief_summary>
	<brief_title>Randomized , Double-blind , Placebo-controlled Study Patients With Fistulizing Crohn 's Disease</brief_title>
	<detailed_description>Beside investigation safety tolerability locally administer DLX105 , purpose study also evaluate response rate time response enterocutaneous fistula follow local injection DLX105 ( secondary objective ) .</detailed_description>
	<mesh_term>Crohn Disease</mesh_term>
	<criteria>Diagnosis Crohn ' Disease Single multiple enterocutaneous abdominal and/or perianal and/or rectovaginal fistula least 3 months'duration . TNFblocker naive patient patient primary secondary antiTNF nonresponders CDAI great 450 ongoing treatment TNFblockers ( duration washout prior randomization 8 week ) Active abscess formation within fistula Abdominal anorectal surgery within last 4 week prior randomization Known immunosuppression Infections , sepsis Positive Test hepatitis B C HIV Patients life vaccination within 6 week prior first study drug administration , require live vaccination course trial Active liver disease ALT and/or AST great 3x upper limit normal Any severe , progressive uncontrolled medical condition judgment investigator prevents patient participate study . History evidence drug alcohol abuse within 6 month prior first study drug administration Pregnant nursing woman , pregnancy define state female conception termination gestation , confirm positive BhCG laboratory test</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>non-invasive management</keyword>
	<keyword>Fistula</keyword>
	<keyword>Crohn 's Disease</keyword>
	<keyword>local administration</keyword>
	<keyword>non-invasive</keyword>
</DOC>